CoChat

Serotonin and Serotonin Antagonism in Cardiovascular and Non‐Cardiovascular Disease

Frishman, William H., Huberfeld, Seymour, Okin, Stuart, Wang, Yuh‐Huey, Kumar, Anil, Shareef, Babar · 1995 · The Journal of Clinical Pharmacology
Cited by 89

The DOI matches its Crossref record.

Abstract

Serotonin, or 5‐hydroxytryptamine, is a naturally‐occurring vasoactive substance found primarily in the brain, enterochromaffin tissue, and blood platelets. It has diffuse cardiophysiologic effects. The multiple effects of serotonin on blood vessels can be explained by the existence of 2 serotonergic receptor subtypes (the S 1 receptor mediates vasodilation, and the S 2 receptor vasoconstriction). Serotonin via the S 2 receptor also augments the actions of several other vasoconstricting substances. Serotonin may be responsible for causing, or at least perpetuating, some forms of systemic hypertension through peripheral and central nervous system (CNS) actions. Ketanserin is a highly selective S 2‐serotonergic antagonist with additional α‐adrenergic blocking activity, which has been proposed as a therapy for various cardiovascular diseases including hypertension. It has been shown to be more effective than placebo in treating hypertension and comparable in effectiveness to other antihypertensive drugs. Its major side effects relate to the CNS, and prolongation of the electrocardiogram QT interval has been described. Caution must be used when using ketanserin in patients receiving potassium‐ and magnesium‐losing agents, because of the risk of torsades de pointes. Ketanserin has potential utility in the treatment of eclampsia, peripheral vascular disease, carcinoid syndrome, and “shock lung.” The drug is not yet approved for clinical use in the United States.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/j.1552-4604.1995.tb05013.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 89

Metadata

Authors
Frishman, W. H., Huberfeld, S., Okin, S., Wang, Y., Kumar, A., & Shareef, B.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
1995-06
Volume
35
Issue
6
Pages
541-572
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2127180891
Cited by
89
References
0
FWCI
3.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serotonin and Serotonin Antagonism in Cardiovascular and Non‐Cardiovascular Disease. https://app.cochat.ai/papers/10.1002/j.1552-4604.1995.tb05013.x
The paper
Frishman, W. H., Huberfeld, S., Okin, S., Wang, Y., Kumar, A., & Shareef, B. (1995). Serotonin and Serotonin Antagonism in Cardiovascular and Non‐Cardiovascular Disease. The Journal of Clinical Pharmacology. https://doi.org/10.1002/j.1552-4604.1995.tb05013.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.